March 5, 2026 7:35am

Circuit breaker have been pushed; BUY slowly, SELL quickly before “uncle algo and his electronic trading dwarfs” get to tick

Earnings: Regenxbio (RGNX)

As I wrote last night, “Stay Frosty; Better informed than sorry, hedge exposure, always have options”

Pre-Open Signals: 2 Negative and 1 Positive Indications

Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.

Never leave retail investor uninformed … I say what others won’t, so you can KNOW what others can’t!

 

Say/write less, mean more …

Wednesday’s RMi Closing Bell: Stay frosty … https://www.regmedinvestors.com/articles/14336

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Thursday: The pre-open Dow futures are DOWN -0.25% or (-124 points), the S&P futures are DOWN -0.07% or (-5 points) and the Nasdaq futures are DOWN -0.13% or (-27 points)

  • U.S. stock futures are floating down on Thursday, 3/5
  • European markets traded higher,
  • Asia Pacific markets rebounded after several sessions of steep losses

Economic Data: weekly jobless claims

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Wednesday: The Dow closed up +238.14 points or +0.49%, the S&P closed UP +52.87 points or +0.78% while the Nasdaq closed UP +290.793 points or +1.29%
  • Tuesday: The Dow closed DOWN -403.51 points or -0.83%, the S&P closed DOWN -64.99 points or -0.94% while the Nasdaq closed DOWN -232.167 points or -1.02%
  • Monday: The Dow closed DOWN -73.14 points or -0.15%, the S&P closed UP +2.74 points or +0.04% while the Nasdaq closed UP +80.646 points or +0.36%
  • Last week: The Dow finished down 1.3% for the week, the NASDAQ declined 0.9%, and the S&P 500 slipped 0.4%. 
  • The previous week: The S&P 500 was up +1.1%, the Dow +0.3% and the Nasdaq was up +1.5%.
  • February: the Dow inclined +0.2%, the Nasdaq dived -3.3% and S&P 500 declined -1%.
  • January: The S&P 500, Dow were up more than 1% and the Nasdaq had a 0.7% gain.

 

Q1/26 – Q1 – March – 1 positive and 2 negative closes

  • February – 1 market holiday, 11 positive and 8 negative closes
  • January – 2 holiday, 2 neutral, 9 negative and 9 positive closes 

Q4:

  • December, 1 holiday, 8 positive and 12 negative closes
  • November, 1 holiday, 8 positive and 11 negative sessions
  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Multiple earnings coming as sector releases Qs and FY25 …

A doubting Thomas – yet …

Alnylam Pharmaceuticals (ALNY) closed up +$8.65 after Tuesday’s -$6.42 after Monday’s -$7.85 with a positive +$1.65 or +0.50% preopen

Capricor Therapeutics (CAPR) closed down -$0.34 with a negative -$0.15 or -0.59% pre-open

Moderna (MRNA) closed up +$7.97 with a negative -$0.36 or -0.62% pre-open

 

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

“I hate to be considered negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Are the dice … hot, as they say it is STILL a “crap shoot”        

  • Keep that in mind   the latest batch of buying opportunities. If you take advantage, you have to be nimble, cutting losers quickly and not letting small winners turn into losers. <IBD>

 

Investors has been looking for further insight into sector earnings; the Q4 and FY25 earnings reporting cycle. So far …

  • Tuesday - 2/24 – AxoGen (AXGN), Beam Therapeutics (BEAM) and Supernus Therapeutics (SUPN)
  • Wednesday – 2/25 – MiMedx (MDXG), Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT)
  • Thursday – 2/26 – Intellia Therapeutics (NTLA), Wave Life Sciences (WVE), Mesoblast (MESO), Vericel (VCEL) and BioLife Solutions (BLFS)
  • Monday – 3/2 uniQure NV (QURE)
  • Thursday - 3/5 Regenxbio (RNX)
  • Tuesday – 3/10 – BioNTech, SE (BNTX)

 

Welcome to my world of defining the “grey’ in our universe!

  • I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
  • if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

March – 1st week

  • 3 /4 – Wednesday closed positive with 32 incliners, 6 decliners and 2 flats
  • 3/3 - Tuesday closed negative with 2 incliners, 36 decliners and 2 flats
  • 3/2 - Monday closed negative with 15 incliners, 23 decliners and 3 flats

February – last week

  • 2/27 – Friday closed negative with 12 incliners, 26 decliners and 2 flats
  • 2/26 – Thursday closed positive with 24incliners, 14 decliners and 2 flats
  • 2/25 – Wednesday closed positive with 20 incliners, 19 decliners and 1 flat
  • 2/24 - Tuesday closed positive with 32 incliners, 5 decliners and 3 flats
  • 2/23 - Monday closed positive with 24 incliners, 13 decliners and 3 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.